中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

58 records (took 0.012 seconds)

    CD31SHED AS A MOLECULAR TARGET FOR IMAGING OF INFLAMMATION
    1.
    发明申请
    CD31SHED AS A MOLECULAR TARGET FOR IMAGING OF INFLAMMATION 审中-公开
    CD31SHED作为炎症成像的分子靶点

    公开(公告)号：WO2017191214A1

    公开(公告)日：2017-11-09

    申请号：PCT/EP2017/060574

    申请日：2017-05-03

    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7 ,  UNIVERSITE PARIS 13 - PARIS NORD ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ,  INSTITUT PASTEUR

    Inventor： BAY, Sylvie ,  NICOLETTI, Antonino ,  LE GULUDEC, Dominique ,  VIGNE, Jonathan ,  CALIGIURI, Giuseppina

    IPC: A61K51/08 ,  A61K103/10 ,  G01N33/60 ,  C07K7/06 ,  A61P29/00

    Abstract: The present invention relates to CD31 shed for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31 shed ligand in different rat models of inflammation indeed showed that CD31 shed is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31 shed present on activated circulating cells and on other organs or cells not involved in inflammation was little. The present invention thus also relates to a labeled CD31 shed ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.

    Abstract translation: 本发明涉及在炎性病症的分子成像中用作分子成像靶标的CD31宿主。 在不同的大鼠炎症模型中给予放射性标记的肽P8RI作为CD31配体配体确实表明CD31在脱落的细胞中以允许可检测信号的量存在，而噪声 在活化的循环细胞上以及在其他器官或未参与炎症的细胞上存在CD31对应的信号很少。 本发明因此还涉及标记的CD31脱落配体及其在炎性病症的分子成像中作为分子成像剂的用途。 炎症位点的分子成像特别允许确定受试者是否患有炎性病症或处于患有炎性病症的风险中或在抗炎治疗后处于炎症状况复发的风险中。

    IMPROVED N4 CHELATOR CONJUGATES
    6.
    发明申请
    IMPROVED N4 CHELATOR CONJUGATES 审中-公开

    公开(公告)号：WO2006008496A3

    公开(公告)日：2006-01-26

    申请号：PCT/GB2005/002807

    申请日：2005-07-19

    Applicant: GE HEALTHCARE LIMITED ,  STOREY, Anthony Eamonn ,  WADSWORTH, Harry ,  POWELL, Nigel Anthony ,  DUNCANSON, Philip

    Inventor： STOREY, Anthony Eamonn ,  WADSWORTH, Harry ,  POWELL, Nigel Anthony ,  DUNCANSON, Philip

    IPC: A61K51/04 ,  A61K51/08 ,  A61K103/10

    Abstract: The present invention provides tetra-amine chelator conjugates with biological targeting moieties, linked via a linker group and technetium complexes thereof as radiopharmaceuticals. The linker group is such that the chelator is mono-functionalised at the bridgehead position and provides both flexibility and a lack or aryl groups, to minimise lipophilicity and steric bulk. Protected versions of the chelators are provided, which permit conjugation with a wide range of targeting molecules without interfering reactions with the amine nitrogens of the tetra-amine chelator. Syntheses of the functionalised chelators are described, together with bifunctional chelate precursors. Radiopharmaceutical compositions comprising the technetium metal complexes of the invention are described, together with non-radioactive kits for the preparation of such radiopharmaceuticals.

    ANTIVIRAL AND ANTIRETROVIRAL RADIOIMMUNOMEDICAMENTS BASED ON alpha -EMITTERS AND beta -EMITTERS
    8.
    发明申请
    ANTIVIRAL AND ANTIRETROVIRAL RADIOIMMUNOMEDICAMENTS BASED ON alpha -EMITTERS AND beta -EMITTERS 审中-公开
    抗病毒和抗逆转录病毒RADIO免疫PHARMAKA基于阿尔法 - β发射器和

    公开(公告)号：WO0000223A3

    公开(公告)日：2000-02-17

    申请号：PCT/DE9901894

    申请日：1999-06-29

    Applicant: BERGTER WOLFGANG

    Inventor： BERGTER WOLFGANG

    IPC: A61K51/00 ,  A61K39/395 ,  A61K51/10 ,  A61K103/00 ,  A61K103/10 ,  A61P1/16 ,  A61P31/12 ,  A61P35/00

    CPC classification number: A61K51/1006 ,  A61K51/1027 ,  A61K51/1093

    Abstract: The invention relates to a pharmaceutical preparation comprising a radioimmunological conjugate (RIK) for in-vivo elimination of virus-replicating cells in HIV-1, HIV-2, HIV-3, HTLV-1, HTLV-2, HBV, HCV, HDV, CMV, EBV, HHV8 infections and in other chronic virus infections. The radioimmunological conjugate is characterized in that it contains, as immunologically effective constituents; d) a monoclonal antibody or the antigen-binding fragment thereof against a viral or virus-induced antigen expressed on the plasma membrane of virus-infected cells, or; e) a receptor molecule or the fragment thereof with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells; or f) a fragment of the cellular receptor molecule, said fragment being modified by mutagenesis, with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells. Said conjugate is also characterized in that it contains d) an alpha emitter or a beta emitter as a radioactive constituent. The inventive pharmaceutical preparation also optionally comprises a pharmaceutical carrier and/or adjuvant.

    Abstract translation: 描述的本发明涉及包含放射性免疫缀合物（RIK）用于体内消除virusreplizierender细胞在HIV-1，HIV-2，HIV-3，HTLV-1，HTLV-2，HBV的药物组合物 ，HCV，HDV，CMV，EBV，HHV8-和其它慢性病毒感染，其特征在于，它被表示为单克隆抗体免疫学上有效组分d）或针对在质膜上的病毒感染病毒的细胞中的抗原结合片段 或病毒诱导的抗原，或e）的受体分子或与亲和它们的片段用于在受感染的细胞的质膜上表达的病毒结构蛋白的表位，或f）一个由具有亲和力的细胞受体分子的诱变片段用于感染在质膜上的细胞的表位修饰 表达病毒结构蛋白，并且它含有放射性成分d）α发射体或β发射体 和任选的药物载体和/或赋形剂。

Patent Agency Ranking